Murine Models of Alcohol Consumption: Imperfect but Still Potential Source of Novel Biomarkers and Therapeutic Drug Discovery for Alcoholic Liver Disease.
Murine Models of Alcohol Consumption: Imperfect but Still Potential Source of Novel Biomarkers and Therapeutic Drug Discovery for Alcoholic Liver Disease.
复制标题
饮酒的鼠模型：新型生物标志物和酒精性肝病的治疗药物发现的不完善但仍有潜在的来源。
DOI：
10.33696/immunology.3.096
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Aloman C
中科院分区：
文献类型：
--
作者：
Alharshawi K;Aloman C
肝脏疾病的动物模型对于加强我们对人类肝脏疾病的认识和理解至关重要。利用小鼠酒精消耗模型研究酒精性肝损伤，以开发新的治疗靶点。被广泛接受和常用的小鼠慢性酒精消耗模型是Meadows-Cook （MC）和Lieber-DeCarli （LD）。LD模型是基于等热量高脂肪的液体饮食，而MC模型小鼠是在正常的食物饮食中添加酒精的饮用水。在现实世界中，酒精性肝病经常被诊断为肥胖和高脂肪摄入的患者，反映了LD饮食。临床医生和病理学家很难区分乙醇和肥胖的重叠特异性作用。在这篇评论中，我们将进一步讨论我们的研究结果，比较MC和LD作为分析早期酒精与增加脂肪摄入对肝脏有害影响的工具。对这两个模型的批判性分析可以为区分酒精对肝脏的具体影响与酒精和饮食的综合影响提供证据。最终，这些研究可以发现个性化酒精性肝损伤的潜在生物标志物和治疗靶点。
Animal models of liver disease are fundamentally important to strengthen our knowledge and understanding of human liver diseases. Murine models of alcohol consumption are utilized to investigate alcoholic liver injury to develop new therapeutic targets. The well accepted and commonly used murine models of chronic alcohol consumption are Meadows-Cook (MC) and Lieber-DeCarli (LD). LD model is based on an isocaloric high-fat liquid diet, but mice under the MC model fed on a regular chow diet with alcohol added to the drinking water. Alcoholic liver disease in real world is frequently diagnosed in patients with obesity and high fat intake, mirroring LD diet. The overlap of the specific effect of ethanol and obesity is difficult to differentiate by clinician and pathologist. In this commentary, we will further discuss our research findings comparing MC and LD as a tool to dissect early alcohol versus increased fat intake detrimental effects on the liver. The critical analysis of these two models could provide evidence to differentiate the specific impact of alcohol on the liver from the combined influence of alcohol and diet. Ultimately, these investigations could uncover potential biomarkers and therapeutic targets for personalized type of alcoholic liver injury.